UCSF

UC San Francisco Previously Published Works

Title

Salvage High-Dose-Rate Brachytherapy for Recurrent Prostate Cancer After Definitive Radiation.

Permalink

<https://escholarship.org/uc/item/92p8r6s7>

Journal

Practical radiation oncology, 11(6)

ISSN

1879-8500

Authors

Wu, Susan Y
Wong, Anthony C
Shinohara, Katsuto
et al.

Publication Date

2021-11-01

DOI

10.1016/j.prro.2021.04.007

Peer reviewed

International Journal of Radiation Oncology • Biology • Physics

Salvage high dose rate brachytherapy for recurrent prostate cancer after definitive radiation

--Manuscript Draft--

Manuscript Number:	
Article Type:	Full Length Article
Section/Category:	Clinical Investigation - Genitourinary Cancers
Corresponding Author:	I-Chow Joe Hsu, M.D. University of California San Francisco San Francisco, CA UNITED STATES
First Author:	Susan Yao Wu, M.D.
Order of Authors:	Susan Yao Wu, M.D. Anthony C. Wong, MD, PhD Katsuto Shinohara, MD Mack Roach, MD J. Adam M. Cunha, PhD Gilmer Valdes, PhD I-Chow Hsu, MD
Abstract:	<p>Purpose: Salvage high-dose-rate brachytherapy (sHDRBT) for locally recurrent prostate cancer after definitive radiation is associated with biochemical control in approximately half of patients at 3-5 years. Given potential toxicity, patient selection is critical. We present our institutional experience with sHDRBT and validate a recursive partitioning machines model for biochemical control.</p> <p>Materials and Methods: We performed a retrospective analysis of 129 patients who underwent whole-gland sHDRBT between 1998-2016. We evaluated clinical factors associated with biochemical control as well as toxicity.</p> <p>Results: At diagnosis the median PSA was 7.77 ng/mL. Majority of patients had T1-2 (73%) and Gleason 6-7 (82%) disease. 71% received external beam RT alone, while 22% received permanent prostate implants. The median DFI was 56 months, and median pre-salvage PSA was 4.95ng/mL. At sHDRBT, 46% had T3 disease and 51% had Gleason 8-10 disease.</p> <p>At a median of 68 months following sHDRBT, 3 and 5-year disease free survival were 87% (95% CI 80-93%) and 69% (95% CI 60-78%), respectively. Median PSA nadir was 0.18 ng/mL, achieved a median of 10 months after sHDRBT. Patients with $\geq 35\%$ cores and a DFI < 4.1 years had worse biochemical control (19% vs. 50%, $p = 0.02$). 14 patients (11%) developed acute urinary obstruction requiring Foley placement while and 19 patients (15%) developed strictures requiring dilation.</p> <p>Conclusions: sHDRBT is a reasonable option for patients with locally recurrent prostate cancer following definitive RT. Those with $< 35\%$ cores or an initial DFI of ≥ 4.1 years may be more likely to achieve long-term disease control following sHDRBT.</p>

I-Chow Joe Hsu, MD FACR
Professor
Radiation Oncology
University of California,
San Francisco
1600 Divisadero Street, H1031
San Francisco, CA 94143
tel: 415/353-7175
fax: 415/353-9883
ihsu@radnoc.ucsf.edu

April 23, 2020

Anthony Zietman, MD, FASTRO
Editor-in-Chief

Dear Dr. Zietman,

Thank you for considering our manuscript, titled "*Salvage high dose rate brachytherapy for recurrent prostate cancer after definitive radiation*".

This manuscript describes our institutional experience with salvage high-dose-rate brachytherapy for prostate cancer after definitive radiation from November 1998-December 2016.

We believe this represents the largest series of salvage high-dose-rate brachytherapy to date and identifies potential clinical criteria that can be used to improve patient selection. It adds to the literature regarding acute and late side effects following salvage brachytherapy for prostate cancer, given the recent toxicity data published from RTOG 0526¹, and offers data on biochemical control while we await those oncologic outcomes.

All authors contributed equally to this work, and have approved the manuscript for submission. This work has not been published previously. There are no financial or other conflicts of interest that may influence the content of this manuscript.

We feel this paper is well suited for *IJROBP* and thank you for your consideration.

Sincerely,

I-Chow Hsu, MD, FASTRO
Department of Radiation Oncology
University of California, San Francisco

Reference:

1. Crook JM, Zhang P, Pisansky TM, *et al.* A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526). *Int. J. Radiat. Oncol. Biol. Phys.* 2019;103:335–343.

Salvage high dose rate brachytherapy for recurrent prostate cancer after definitive radiation

Susan Y. Wu, MD¹; Anthony C. Wong, MD, PhD¹; Katsuto Shinohara, MD²; Mack Roach III, MD¹; J. Adam M. Cunha¹, PhD; Gilmer Valdes, PhD¹; I-Chow Hsu, MD¹

¹Department of Radiation Oncology, University of California, San Francisco; San Francisco, CA

²Department of Urology, University of California, San Francisco; San Francisco, CA

Corresponding author:

I-Chow Hsu, MD
1825 Fourth St., M1215
San Francisco, CA 94158
Phone: 415 514-2070
Fax: 415 476-7370
I-Chow.Hsu@ucsf.edu

Running title:

Salvage high-dose rate brachytherapy for recurrent prostate cancer

Word count: 3546

Abstract word count: 250

Acknowledgements or financial support: Dr. Valdes has been partially funded by the National Institute Of Biomedical Imaging And Bioengineering of the National Institutes of Health under Award Number K08EB026500.

COI notification:

The authors have no conflicts of interest.

Data Sharing: Research data are stored in an institutional repository and will be shared upon request to the corresponding author.

Abbreviations:

ADT: androgen deprivation therapy
CTCAE: Common Terminology Criteria for Adverse Events
DFI: Disease free interval
DFS: disease free survival
EBRT: external beam radiotherapy
FDG: Fluorodeoxyglucose
GI: gastrointestinal
GU: genitourinary
HDRBT: high-dose-rate brachytherapy
IQR: interquartile range
NED: no [without] evidence of disease
OS: overall survival
PNI: perineural invasion
PPI: permanent prostate implants
PSA: prostate specific antigen
PSMA: Prostate specific membrane antigen
RT: radiation
SBRT: stereotactic body radiotherapy
sHDRBT: salvage high-dose-rate brachytherapy
TRUS: trans-rectal ultrasound

Abstract

Purpose:

Salvage high-dose-rate brachytherapy (sHDRBT) for locally recurrent prostate cancer after definitive radiation is associated with biochemical control in approximately half of patients at 3-5 years. Given potential toxicity, patient selection is critical. We present our institutional experience with sHDRBT and validate a recursive partitioning machines model for biochemical control.

Materials and Methods:

We performed a retrospective analysis of 129 patients who underwent whole-gland sHDRBT between 1998-2016. We evaluated clinical factors associated with biochemical control as well as toxicity.

Results:

At diagnosis the median PSA was 7.77 ng/mL. Majority of patients had T1-2 (73%) and Gleason 6-7 (82%) disease. 71% received external beam RT alone, while 22% received permanent prostate implants. The median DFI was 56 months, and median pre-salvage PSA was 4.95ng/mL. At sHDRBT, 46% had T3 disease and 51% had Gleason 8-10 disease.

At a median of 68 months following sHDRBT, 3 and 5-year disease free survival were 87% (95% CI 80-93%) and 69% (95% CI 60-78%), respectively. Median PSA nadir was 0.18 ng/mL, achieved a median of 10 months after sHDRBT. Patients with $\geq 35\%$ cores and a DFI < 4.1 years had worse biochemical control (19% vs. 50%, $p = 0.02$). 14 patients (11%) developed acute urinary obstruction requiring Foley placement while and 19 patients (15%) developed strictures requiring dilation.

Conclusions:

sHDRBT is a reasonable option for patients with locally recurrent prostate cancer following definitive RT. Those with $< 35\%$ cores or an initial DFI of ≥ 4.1 years may be more likely to achieve long-term disease control following sHDRBT.

Keywords: Salvage brachytherapy, recurrent prostate cancer

Introduction

Biochemical failure following definitive radiation in the treatment of prostate cancer occurs in up to 30% of patients with intermediate to high risk disease, even in the era of dose escalated radiation with brachytherapy(1).

Between 50-70% of patients with biochemical failure will have isolated local failure (2, 3). For these patients, potential salvage treatment options that offer the possibility of long-term disease control include radical salvage prostatectomy, brachytherapy, stereotactic body radiotherapy (SBRT), and cryotherapy. However, the majority of patients do not receive potentially curative treatment, with rates ranging from 2% (5/257) (4) to 16% (97/609) (5). Up to half of patients are not offered any treatment, and rather are managed with observation (4). Zumsteg et al. found that following biochemical failure, the median time to clinically detected distant metastases was 5.4 years, and the median time to prostate cancer-specific mortality was 10.5 years (5). Though the impact of specific local salvage therapies on prostate cancer specific mortality is not clear, there is data to suggest that local failure is associated with the development of distant metastases(6).

Prior series examining the role of salvage HDR brachytherapy (sHDRBT) have demonstrated 2-year biochemical control approaching 90% (7) and 5-year biochemical control of approximately 50% in appropriately selected patients (8, 9). sHDRBT offers dosimetric advantages that help limit dose to the rectum, bladder, and urethra(10), with predominantly grade 2 genitourinary toxicity that compares favorable to other salvage options such as radical prostatectomy (9, 11-13).

Here we update our institutional experience with sHDRBT and validate a previously developed recursive partitioning machines model for biochemical control.

Materials and Methods:

We performed a single institution retrospective review of 153 patients treated with sHDRBT between November 1998 and December 2016. We excluded patients who received pelvic radiotherapy at the time of sHDRBT (n= 11), had partial prostate implants (n= 3), or did not have follow-up PSA measurements available (n=10); our final analysis includes 129 patients. Outcomes for 84 patients have not previously been published, while 45 patients were previously described with shorter follow-up (XXX). Biochemical failure following initial RT and after sHDRBT was defined using the Phoenix criteria (15). Patients were required to have biopsy proven locally recurrent prostate cancer and no evidence of metastatic disease on systemic imaging, which could include CT/MRI and ⁹⁹Tc bone scan, PET/CT, or PET/MRI (tracers included FDG, Na/F, fluciclovine, or ⁶⁸Ga PSMA).

Treatment received:

Patients received 36 Gy in 6 fractions or 32 Gy in 4 fractions, both over 2 implants; this technique has been described previously (7). Dosimetric constraints included V75 <1cc for the bladder and rectum, urethra V125 < 1cc, and D100 >90% of the planning target volume.

Outcomes and Statistics:

Our primary endpoints were disease free survival (DFS) and overall survival (OS) following sHDRBT, which were estimated using the Kaplan-Meier method. Acute and late toxicity was graded according to the Common Terminology Criteria for Adverse Events (CTCAE v5.0). In addition to descriptive statistics, Mann-Whitney tests were used to compare continuous variables while Chi-squared and Cochran-Armitage tests were used

for non-ordered and ordered categorical variables, respectively. Univariate analysis using Cox's proportional hazards regression model was used to identify predictors of biochemical failure; as no variables were found to be statistically significant, a multivariable analysis was not performed. For all analyses, a 2-sided p-value <0.05 was considered statistically significant. Statistical analysis was performed using SPSS v.25 (IBM Corp, Armonk, NY).

Machine learning

Outcomes for an initial cohort of 45 patients were previously analyzed using a recursive partitioning machines model(***), which found that patients with $\geq 35\%$ positive cores and a disease free interval (DFI) < 4.1 years were more likely to experience biochemical failure (75% vs. 38% among patients who did not meet these criteria). Here we evaluate these clinical criteria in a previously unpublished cohort of 84 patients, as well as with longer follow-up among the original cohort.

Results:

Patient characteristics prior to sHDRBT

Patient characteristics in the entire cohort, as well as separated into the original and validation cohort, are shown in Table 1. The median age at initial diagnosis was 60 years (interquartile range (IQR) 56-66) with a median PSA of 7.77 ng/mL (IQR 5.60-11.75). At initial diagnosis, 35% (45/129) had T1c disease, 37% (48/129) had T2 disease, 11% (14/129) had T3a and 9% (11/129) had T3b disease; initial T stage was unknown in 9% (11/129). At initial diagnosis, 42% (54/129) had Gleason 6 disease, 40% (52/129) Gleason 7, 10% (13/129) Gleason 8, and 5% (7/129) Gleason 9-10. All patients were treated with

definitive radiotherapy (RT). The majority received external beam RT (EBRT) alone (71%, 91/129), while 22% (28/129) received permanent prostate implants (PPI); the remaining 10 patients received HDRBT, protons, or stereotactic body radiotherapy. 44% (57/129) received androgen deprivation therapy (ADT) at the time of initial RT. The median PSA nadir after definitive therapy was 0.60 (IQR 0.10-0.90), with a median DFI of 56 months (IQR 39-84).

All patients underwent trans-rectal ultrasound (TRUS) and biopsy confirming recurrence in the prostate prior to consideration for sHDRBT. The majority of patients underwent evaluation for nodal or distant metastatic disease with CT and bone scan (97/129, 75%) or MRI and bone scan (20/129, 16%) prior to sHDRBT. An additional 4% of patients received Prostacint scans, 2% received ⁶⁸Ga-PSMA PET/CT or PET/MRI, and an additional 3% received MRI, FDG or NaF PET/CT, or ⁹⁹Tc bone scan only prior to sHDRBT.

Disease characteristics at sHDRBT

At the time of sHDRBT 24% of patients (31/129) had T1c disease, 29% (37/129) had T2 disease, 19% (25/129) had T3a and 27% (35/129) had T3b disease (Table 1). 5% (7/129) were Gleason 6, 40% (51/129) Gleason 7, 35% (45/129) Gleason 8, and 16% (20/129) Gleason 9-10 at the time of sHDRBT, with a median of 30% positive cores. The median pre-salvage PSA was 4.95 ng/ml (IQR 3.92-6.90). 50% of patients (58/115, 14 unknown) had perineural invasion (PNI) at the time of sHDRBT. Median interval from biochemical failure to sHDRBT was 9 months (IQR 7-18).

Outcomes following sHDRBT

The median post-sHDRBT PSA was 1.07 ng/mL, with a median nadir of 0.18 ng/mL (IQR 0.09-0.51) achieved at a median of 10 months following salvage (IQR 5-21). At a

1
2
3
4 median follow-up of 68 months (IQR 46-105), 46% of patients (59/129) remained without
5
6 evidence of disease (Figure 1). The median time to failure after sHDRBT was 64 months
7
8 (IQR 44-103 months). The Kaplan Meier estimate for 3-year disease free survival was 87%
9
10 (95% CI 80-93%) and for 5-year disease free survival was 69% (95% CI 60-78%).
11
12
13

14 Disease free survival was associated with lower post-sHDRBT PSA nadir (0.10
15
16 ng/mL in those without evidence of disease at last follow-up (NED) vs. 0.37 ng/mL in those
17
18 with biochemical failure (BF), $p < 0.001$), as well as longer interval from sHDRBT to PSA
19
20 nadir (17 months in those who remained NED vs. 7 months in those with BF, $p < 0.001$).
21
22
23

24 On univariate analysis (Table 2), no pre-treatment variables were significantly
25
26 associated with biochemical failure. 36% of patients were treated between 8/2009 and
27
28 6/2014 and received 32 Gy in 4 fractions (46/129), however the majority of patients
29
30 received 36 Gy in 6 fractions (64%, 82/129); all patients received 2 implants. There was a
31
32 trend towards improved DFS in patients treated with 36 Gy in 6 fractions compared to 32
33
34 Gy in 4 fractions (52% vs. 33%, $p = 0.053$) with no significant difference in follow-up
35
36 interval between the two groups (median 63 and 78 months respectively, $p = 0.56$). 28% of
37
38 patients (36/129) received ADT and 8% (10/129) received hyperthermia at the time of
39
40 sHDRBT, though neither were associated with disease free survival at last follow-up ($p =$
41
42 0.37 and $p = 0.29$, respectively).
43
44
45
46
47
48

49 Machine learning validation:

50
51 Patients who had >35% positive cores at salvage, and a disease free interval <4.1
52
53 years were more likely to experience biochemical failure (81% (13/16) vs. 50% (55/109),
54
55 $p = 0.021$ in the total cohort and 82% (9/11) vs. 49% (35/72) in the new cohort ($p =$
56
57 0.040)). As previously predicted(14), when over 100 patients were included in the
58
59
60
61
62
63
64
65

analysis, clinical criteria identified using the recursive partitioning machines model was able to identify subpopulations of patients at risk for biochemical failure with statistical significance(15).

Sites of recurrence

70 patients (54%) developed biochemical failure after sHDRBT (Table 3). 46% (32/70) had failure distantly; of these 32 patients, 28 had distant failure only, while 1 had local and distant, 2 had regional and distant, and 1 had both locoregional and distant failure. Isolated local failure was seen in 7% of patients (9/70), isolated regional failure was seen in 2% (3/70), and locoregional failure was seen in 4% (3/70).

In 18% of patients who experienced biochemical failure (23/70), the site of failure was unknown. Site of failure after biochemical recurrence following sHDRBT was unknown in 8% of patients who received ⁶⁸Ga-PSMA PET imaging (1/12) vs. 38% (22/58) of patients who did not undergo ⁶⁸Ga-PSMA PET imaging. Of the 12 patients who underwent ⁶⁸Ga-PSMA PET scans for biochemical failure after sHDRBT (Table 3), 4 patients were identified with local failure, 3 with locoregional failure, 2 with isolated distant failure, 1 with local and distant, 1 with locoregional and distant failure, and one with unknown site of failure.

Toxicity

Genitourinary (GU) and gastrointestinal (GI) toxicities are summarized in Table 4; for the analyses below late is defined as >3 months, though data for late toxicity >9 months is also presented. Acute and late grade 3 or higher GU toxicities were seen in 1% and 6% of patients, respectively. 40% (51/82) of patients with late grade 2 GU toxicity were classified as such solely because they remained on medications such as tamsulosin. Acute and late grade 3 or higher GI toxicities were seen in 0% and 2% of patients, respectively. There was

no association between acute or late grade 3 toxicity and type of prior radiation treatment (p = 0.99 and p = 0.96 for acute and late GU, and p = 0.97 for late GI; no grade 3 or higher acute GI toxicity).

11% of patients (14/129) required a Foley catheter for acute urinary retention following sHDRBT; this was not associated with type of prior RT though there was a trend towards higher rates of Foley use in those who received prior PPI (17% vs. 11% with other RT modalities, p = 0.09). Obstruction requiring a Foley was not associated with prostate size at sHDRBT (p = 0.10), treatment with hyperthermia (p = 0.91), or prior DFI (p = 0.34).

15% of patients (19/129) developed strictures at a median of 42 months following sHDRBT (95% CI 27-56 months) (Figure 1c). Stricture development was not associated with type of prior RT (p = 0.77), treatment with hyperthermia (p = 0.71), prior DFI (p = 0.18), or prostate size at salvage (p = 0.09).

Four patients developed rectourethral fistulas requiring diversion at 11 months, 13 months, 3.7 years and 6.4 years after completing sHDRBT respectively. Fistula incidence was higher among patients who developed a stricture requiring dilation after sHDRBT (16%, 3/19) than patients who did not develop a stricture requiring dilation (1%, 1/110) (p = 0.001). There was no association between fistula development and time from initial RT to salvage (p = 0.41), follow-up after sHDRBT (p = 0.13), prostate size at salvage (p = 0.96), T-stage at salvage (p = 0.68), type of prior RT (p = 1.00), or hyperthermia at salvage (p = 1.00).

Two patients developed a second malignancy in or adjacent to the radiation field, with one rectal cancer and one urothelial carcinoma diagnosed 6.1 and 3.9 years following sHDRBT, respectively.

Discussion

To our knowledge this represents the largest series of sHDRBT to date and suggests that a significant proportion of patients with locally recurrent prostate cancer after definitive radiation can achieve biochemical control with sHDRBT, though this rate declines with time and argues for rigorous patient selection. In our series sHDRBT was relatively well tolerated.

In patients with isolated local failure, local salvage therapy is the only treatment option with curative intent. Though we lack level 1 evidence demonstrating an OS or DFS benefit to local salvage, we have retrospective data that suggests sequential progression in patients with biochemical failure to clinically detectable metastases after 5.4 years, with a median time to prostate cancer specific mortality of 10.5 years(5). Based on data in the setting of biochemical recurrence following radical prostatectomy, we know that the time from initial local treatment to the development of metastatic disease predicts time to death (17). However rates of local therapy following radiation failure have been reported as low as 2%(4). Androgen deprivation therapy is the most common salvage treatment, used in about 94% of patients undergoing salvage, which corresponds to about 66% of all patients with failure after EBRT (18). Unfortunately as a treatment modality, ADT is palliative, with a median survival of 5-6 years after initiation in patients with metastatic disease, and is also associated with decreased quality of life (19).

Our findings are consistent with previously published series of sHDRBT and demonstrate reasonably high rates of biochemical control at short-term follow-up, with attrition over time. Some series have estimated 5-year biochemical control as high as 70-

1
2
3
4 80% in appropriately selected patients, though rates of approximately 50% are more
5
6 commonly reported (9, 20-22). These rates of biochemical control are comparable to those
7
8 achieved with other salvage treatment modalities, including radical prostatectomy (12, 13,
9
10 23), low dose rate brachytherapy (24-26), and cryotherapy(27, 28). SBRT has more limited
11
12 follow-up, however may also be associated 5-year biochemical disease free survival of 60%
13
14 (29).
15
16
17
18

19 The decline in biochemical control between years 3 and 5 suggests that patient
20
21 selection remains critical. Our current institutional practice is to obtain TRUS and multi-
22
23 parametric MRI-guided biopsy, CT and bone scan, as well as ⁶⁸Ga-PSMA or fluciclovine PET
24
25 imaging if possible. The majority of data using ⁶⁸Ga-PSMA PET imaging for biochemical
26
27 recurrence is following radical prostatectomy (30-32). Limited data in patients with
28
29 biochemical recurrence following definitive EBRT suggests that 17% of patients may have
30
31 isolated local recurrence, 6% local and regional (pelvic lymph nodes), and 19% isolated
32
33 regional failure (33). ⁶⁸Ga-PSMA PET therefore may be a useful tool to identify patients
34
35 more likely to benefit from local salvage. In our series, regional failure following sHDRBT
36
37 was seen in 7/42 patients (17%) without prior nodal radiation and 2/17 patients (12%)
38
39 who received nodal radiation with their initial treatment course (p = 0.22). No patients in
40
41 this series received pelvic nodal radiation at the time of salvage.
42
43
44
45
46
47
48

49 We were also able to validate clinical criteria identified using a recursive
50
51 partitioning machines model for biochemical control. Patients with <35% cores involved or
52
53 ≥35% cores involved with a disease free interval >4.1 years were less likely to experience
54
55 biochemical failure following sHDRBT. Additional clinical factors have been shown to be
56
57 associated with improved disease control after salvage brachytherapy, including PSA
58
59
60
61
62
63
64
65

1
2
3
4 doubling time >6-9 months(34), low PSA < 10 or ≤6(22), and long interval from prior
5
6 radiation(14) which may also improve toxicity (35).
7
8

9 Retrospective series of salvage brachytherapy suggest acute urinary retention in 4%
10 (4/98) of patients, no acute grade 3/4 genitourinary (GU) toxicity, and 9% (9/98) grade
11 3/4 late GU toxicity(36). Though the oncologic outcomes for RTOG 0526 are still pending,
12 toxicity data with a median follow-up of 54 months following salvage low-dose-rate
13
14 brachytherapy demonstrated a 14% rate of late grade 3 GU or GI toxicity, which was not
15
16 associated with pretreatment variables such as prior treatment dose or interval (37). Our
17
18 data suggests a slightly higher rate of acute urinary retention, with 11% of patients
19
20 requiring Foley placement following sHDRBT, however slightly lower rates of late grade 3+
21
22 GU or GI toxicity (6%, with late defined as > 9 months per RTOG 0526).
23
24
25
26
27
28
29
30

31 Our stricture rate of 15% was higher than expected based on the 7% seen in
32
33 Yamada *et al.* (20), as was the prolonged interval of events up to 90 months. Four patients
34
35 developed rectourethral fistulas, also at a variable duration following sHDRBT of up to 44
36
37 months. Our finding that stricture dilation following sHDRBT was associated with
38
39 increased risk of fistula suggests that additional urologic procedures in patients who have
40
41 received salvage local therapy warrants careful deliberation and patient education of
42
43 potential risks. Though our rate of late grade 2 GI or GU toxicity was consistent with
44
45 previously published series (20), with approximately 40% of these patients requiring
46
47 medications to manage their urinary symptoms, further consideration of ways to decrease
48
49 side effects is key.
50
51
52
53
54
55

56 In addition to urethral sparing during treatment planning(10), focal salvage
57
58 brachytherapy may be an option in patients with disease localized to one region of the
59
60
61
62
63
64
65

1
2
3
4 prostate on both imaging and biopsy, with the potential to limit dose to the urethra and
5
6 rectum(38, 39). Partial gland sHDRBT to the involved quadrant based on MRI has been
7
8 reported in a small series of 15 patients and appears well tolerated, with no urinary
9
10 retention and 7% grade 3 GU toxicity, with a 3-year failure free rate of 61% (40). A
11
12 technique using sHDRBT to treat the peripheral zone and PET-avid disease has also been
13
14 reported, with 45% 5-year disease control and no grade 3 toxicity(8). Additional methods
15
16 using a permanent seed technique have been described, and include treating the whole
17
18 gland to 108 Gy while escalating dose to the tumor as seen on MR spectroscopy to 144 Gy
19
20 using ¹³¹I or ¹⁰³Pd seeds (88% biochemical recurrence free survival at a median of 30
21
22 months, 1/37 patients with grade 3 toxicity)(41), as well as partial gland salvage using ¹²⁵I
23
24 seeds with 70% 3-year biochemical recurrence free survival and one grade 3 GU
25
26 toxicity(42, 43).
27
28
29
30
31
32

33
34 A significant limitation to our analysis is the retrospective nature of our data, with
35
36 heterogeneous follow-up and potential underestimation of toxicity as a substantial
37
38 proportion of patients had clinical follow-up with their local referring physicians. Our rate
39
40 of biochemical failure may be an underestimate if biochemical failure was managed by local
41
42 referring physicians. In general however, patients who had clinical follow-up closer to
43
44 home still submitted their PSA measurements to our office and were in communication by
45
46 MyChart, phone or email. We additionally did not limit our analysis to patients with failure
47
48 following external beam radiotherapy alone—24% had definitive brachytherapy, 2% had
49
50 brachytherapy boost, 4% were treated with protons, and 1% treated with SBRT. Increased
51
52 dose to the urethra during definitive RT with these treatment modalities may help explain
53
54 our higher than expected stricture rate, as late GU toxicity has been reported to be lower in
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 patients undergoing salvage SBRT after external beam alone compared to those who were
5
6 treated with more intensive RT modalities(29).
7
8

9
10 Despite including patients treated over an 18-year span, our numbers were still
11 limited, precluding identification of additional clinical variables associated with
12 biochemical control or toxicity. Additionally, our institution did not have fixed criteria in
13
14 place over this period to select patients for sHDRBT. As approximately 30% of patients in
15
16 this series had T3b disease and almost 50% had Gleason 8-10 disease, our cohort likely
17
18 does not reflect patients most likely to achieve long-term disease control with sHDRBT.
19
20 Specific selection criteria for salvage local therapy have been proposed(44), and warrant
21
22 further investigation. It also must also be noted that we used the Phoenix definition of
23
24 biochemical failure(15), which was developed to describe outcomes following external
25
26 beam radiation with or without ADT. Though this definition has been published in other
27
28 series of salvage brachytherapy after radiation(9, 41) and is the definition used in RTOG
29
30 0526, other criteria have also been reported, including 2(24) or 3(34) successive increases
31
32 in PSA above the nadir.
33
34
35
36
37
38
39
40
41
42
43

44 **Conclusions**

45
46 For patients with local recurrence after definitive radiotherapy, sHDRBT offers the
47
48 potential for long-term disease control with an acceptable toxicity profile. Optimal patient
49
50 selection remains critical, and those with $\geq 35\%$ positive cores and prior DFI <4.1 years
51
52 may be at higher risk of occult metastatic disease.
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure Captions:

Figure 1. A) Overall survival, B) disease free survival, and C) and stricture-free survival following sHDRBT using the Kaplan Meier method

References:

1. Morris WJ, Tyldesley S, Rodda S, *et al.* Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer. *Int. J. Radiat. Oncol. Biol. Phys.* 2017;98:275–285.
2. Zagars GK, Pollack A, Eschenbach von AC. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen. *IJROBP.* 1995;33:23–35.
3. Zumsteg ZS, Spratt DE, Romesser PB, *et al.* Anatomical Patterns of Recurrence Following Biochemical Relapse in the Dose Escalation Era of External Beam Radiotherapy for Prostate Cancer. *The Journal of Urology.* 2015;194:1624–1630.
4. Tran H, Kwok J, Pickles T, *et al.* Underutilization of local salvage therapy after radiation therapy for prostate cancer. *Urol. Oncol.* 2014;32:701–706.
5. Zumsteg ZS, Spratt DE, Romesser PB, *et al.* The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy. *European Urology.* 2015;67:1009–1016.
6. Coen JJ, Zietman AL, Thakral H, *et al.* Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. *Journal of Clinical Oncology.* 2002;20:3199–3205.
7. Lee B, Shinohara K, Weinberg V, *et al.* Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience. *IJROBP.* 2007;67:1106–1112.
8. Jiang P, van der Horst C, Kimmig B, *et al.* Interstitial high-dose-rate brachytherapy as salvage treatment for locally recurrent prostate cancer after definitive radiation therapy: Toxicity and 5-year outcome. *Brachytherapy.* 2017;16:186–192.
9. Chen CP, Weinberg V, Shinohara K, *et al.* Salvage HDR Brachytherapy for Recurrent Prostate Cancer After Previous Definitive Radiation Therapy: 5-Year Outcomes. *International Journal of Radiation Oncology*Biophysics.* 2013;86:324–329.
10. Cunha JAM, Pouliot J, Weinberg V, *et al.* Urethra low-dose tunnels: Validation of and class solution for generating urethra-sparing dose plans using inverse planning simulated annealing for prostate high-dose-rate brachytherapy. *Brachytherapy.* 2012;11:348–353.
11. Kukielka AM, Hetnał M, Dąbrowski T, *et al.* Salvage prostate HDR brachytherapy combined with interstitial hyperthermia for local recurrence after radiation therapy failure. *Strahlenther Onkol.* 2014;190:165–170.
12. Yuh B, Ruel N, Muldrew S, *et al.* Complications and outcomes of salvage robot-assisted radical prostatectomy: a single-institution experience. *BJU International.* 2014;113:769–

776.

13. Bianco FJ, Scardino PT, Stephenson AJ, *et al.* Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. *IJROBP*. 2005;62:448–453.

14. Valdes G, Chang AJ, Interian Y, *et al.* Salvage HDR Brachytherapy: Multiple Hypothesis Testing Versus Machine Learning Analysis. *Int. J. Radiat. Oncol. Biol. Phys.* 2018;101:694–703.

15. Roach M, Hanks G, Thames H, *et al.* Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. In: Vol 65. 2006:965–974.

16. Valdes G, Luna JM, Eaton E, *et al.* MediBoost: a Patient Stratification Tool for Interpretable Decision Making in the Era of Precision Medicine. *Scientific Reports*. 2016;6:37854.

17. Pound CR, Partin AW, Eisenberger MA, *et al.* Natural history of progression after PSA elevation following radical prostatectomy. *JAMA*. 1999;281:1591–1597.

18. Agarwal PK, Sadetsky N, Konety BR, *et al.* Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. *Cancer*. 2008;112:307–314.

19. Hussain M, Tangen CM, Berry DL, *et al.* Intermittent versus continuous androgen deprivation in prostate cancer. *N Engl J Med*. 2013;368:1314–1325.

20. Yamada Y, Kollmeier MA, Pei X, *et al.* A Phase II study of salvage high-dose-rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy. *Brachytherapy*. 2014;13:111–116.

21. Wojcieszek P, Szlag M, Głowacki G, *et al.* Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer after primary radiotherapy failure. *Radiother Oncol*. 2016;119:405–410.

22. Łyczek J, Kawczyńska MM, Garmol D, *et al.* HDR brachytherapy as a solution in recurrences of locally advanced prostate cancer. *jcb*. 2009;1:105–108.

23. Chade DC, Shariat SF, Cronin AM, *et al.* Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. *European Urology*. 2011;60:205–210.

24. Grado GL, Collins JM, Kriegshauser JS, *et al.* Salvage brachytherapy for localized prostate cancer after radiotherapy failure. *Urology*. 1999;53:2–10.

25. Burri RJ, Stone NN, Unger P, *et al.* Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer. *Int. J. Radiat. Oncol. Biol. Phys.* 2010;77:1338–1344.
26. Lacy JM, Wilson WA, Bole R, *et al.* Salvage Brachytherapy for Biochemically Recurrent Prostate Cancer following Primary Brachytherapy. *Prostate Cancer*. 2016;2016:9561494–9.
27. Williams AK, Martínez CH, Lu C, *et al.* Disease-free survival following salvage cryotherapy for biopsy-proven radio-recurrent prostate cancer. *European Urology*. 2011;60:405–410.
28. Pisters LL, Rewcastle JC, Donnelly BJ, *et al.* Salvage prostate cryoablation: initial results from the cryo on-line data registry. *The Journal of Urology*. 2008;180:559–63– discussion 563–4.
29. Fuller D, Wurzer J, Shirazi R, *et al.* Retreatment for Local Recurrence of Prostatic Carcinoma After Prior Therapeutic Irradiation: Efficacy and Toxicity of HDR-Like SBRT. *Int. J. Radiat. Oncol. Biol. Phys.* 2020;106:291–299.
30. Habl G, Sauter K, Schiller K, *et al.* (68) Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment. *Prostate*. 2017;77:920–927.
31. Calais J, Czernin J, Cao M, *et al.* 68Ga-PSMA PET/CT mapping of prostate cancer biochemical recurrence following radical prostatectomy in 270 patients with PSA<1.0ng/ml: Impact on Salvage Radiotherapy Planning. *J. Nucl. Med.* 2017;jnumed.117.201749.
32. Boreta L, Gadzinski AJ, Wu SY, *et al.* Location of Recurrence by Gallium-68 PSMA-11 PET Scan in Prostate Cancer Patients Eligible for Salvage Radiotherapy. *Urology*. 2019;129:165–171.
33. Hruby G, Eade T, Kneebone A, *et al.* Delineating biochemical failure with (68)Ga-PSMA-PET following definitive external beam radiation treatment for prostate cancer. *Radiother Oncol.* 2017;122:99–102.
34. Beyer DC. Permanent brachytherapy as salvage treatment for recurrent prostate cancer. *Urology*. 1999;54:880–883.
35. Nguyen PL, Chen M-H, D'amico AV, *et al.* Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer. *Cancer*. 2007;110:1485–1492.
36. Kollmeier MA, McBride S, Taggar A, *et al.* Salvage brachytherapy for recurrent prostate cancer after definitive radiation therapy: A comparison of low-dose-rate and high-dose-rate brachytherapy and the importance of prostate-specific antigen doubling time. *Brachytherapy*. 2017;16:1091–1098.

37. Crook JM, Zhang P, Pisansky TM, *et al.* A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526). *Int. J. Radiat. Oncol. Biol. Phys.* 2019;103:335–343.
38. Zamboglou C, Rischke HC, Meyer PT, *et al.* Single fraction multimodal image guided focal salvage high-dose-rate brachytherapy for recurrent prostate cancer. *jcb.* 2016;8:241–248.
39. Maenhout M, Peters M, van Vulpen M, *et al.* Focal MRI-Guided Salvage High-Dose-Rate Brachytherapy in Patients With Radiorecurrent Prostate Cancer. *Technol. Cancer Res. Treat.* 2017;16:1194–1201.
40. Murgic J, Morton G, Loblaw A, *et al.* Focal Salvage High Dose-Rate Brachytherapy for Locally Recurrent Prostate Cancer After Primary Radiation Therapy Failure: Results From a Prospective Clinical Trial. *Int. J. Radiat. Oncol. Biol. Phys.* 2018;102:561–567.
41. Aaronson DS, Yamasaki I, Gottschalk A, *et al.* Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy. *BJU International.* 2009;104:600–604.
42. Hsu CC, Hsu H, Pickett B, *et al.* Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer. *Int. J. Radiat. Oncol. Biol. Phys.* 2013;85:370–377.
43. Peters M, Maenhout M, van der Voort van Zyp JRN, *et al.* Focal salvage iodine-125 brachytherapy for prostate cancer recurrences after primary radiotherapy: a retrospective study regarding toxicity, biochemical outcome and quality of life. *Radiother Oncol.* 2014;112:77–82.
44. Tisseverasinghe SA, Crook JM. The role of salvage brachytherapy for local relapse after external beam radiotherapy for prostate cancer. *Transl Androl Urol.* 2018;7:414–435.

Table 1. Patient characteristics

Variable	Total cohort (n=129, %)	Prior cohort (n=45)	Validation cohort (n=84)	p-value
Age at diagnosis, Med (IQR)	60 (56-66)	60 (54-64)	62 (58-71)	0.95
Pre-tx PSA, med ng/mL (IQR)	7.77 (5.60- 11.75)	9.00 (6.40- 12.60)	6.10 (5.43- 9.88)	0.007
T-stage at dx				0.039
1c	45 (35%)	9 (20%)	36 (43%)	
2a/b	38 (30%)	21 (47%)	17 (20%)	
2c	10 (8%)	1 (2%)	9 (11%)	
3a	14 (11%)	7 (16%)	7 (8%)	
3b	11 (9%)	6 (13%)	5 (6%)	
Unknown	11 (9%)	1 (2%)	10 (12%)	
Pre-tx Gleason score				.60
5	3 (2%)	2 (4%)	1 (1%)	
6	54 (42%)	21 (47%)	33 (40%)	
7 (3+4 and 4+3)	52 (40%)	14 (31%)	38 (45%)	
8	13 (10%)	5 (11%)	8 (18%)	
9/10	7 (5%)	3 (7%)	4 (5%)	
Percent cores at diagnosis, median (IQR)	50% (23-71%)	67% (38- 86%)	37% (18-69%)	0.068
Definitive RT				0.057
EBRT alone	91 (71%)	37 (82%)	54 (64%)	
PPI	28 (22%)	5 (11%)	23 (27%)	
HDR	2 (2%)	0 (0%)	2 (2%)	
EBRT+brachy	2 (2%)	2 (4%)	0 (0%)	
Protons	5 (4%)	1 (2%)	4 (5%)	
SBRT	1 (1%)	0 (0%)	1 (1%)	
Prior ADT				0.044
Short-term	40 (31%)	16 (36%)	50 (60%)	
Long-term	17 (13%)	9 (20%)	24 (29%)	
No	70 (54%)	20 (44%)	8 (10%)	
Unknown	2 (2%)	0 (0%)	2 (2%)	
PSA nadir after definitive therapy	0.60 (0.10- 0.90)	0.60 (0.05- 1.12)	0.45 (0.12- 0.70)	0.50
Prior disease free interval (mo)	56 (39-84)	53 (33-78)	58 (43-87)	0.27
Time PSA failure to salvage (mo)	9 (7-18)	9 (3-16)	10 (8-21)	0.47
Pre-salvage PSA	4.95 (3.92- 6.90)	5.50 (4.12- 6.77)	4.75 (3.81- 7.75)	0.83
Salvage T stage				0.20
1c	31 (24%)	6 (13%)	25 (30%)	

2a/b	30 (23%)	12 (27%)	18 (21%)	
2c	7 (5%)	2 (4%)	6 (7%)	
3a	25 (19%)	16 (36%)	9 (11%)	
3b	35 (27%)	10 (22%)	25 (30%)	
Unknown	1 (1%)	0 (0%)	1 (1%)	
Salvage GS				0.43
6	7 (5%)	2 (4%)	5 (6%)	
7	51 (40%)	8 (18%)	13 (15%)	
8	45 (35%)	11 (24%)	19 (22%)	
9/10	20 (16%)	16 (36%)	29 (35%)	
Unknown	6 (5%)	4 (9%)	16 (19%)	
% positive cores at salvage	30% (15-50%)	40% (23-50%)	31% (15-57%)	0.41
Salvage dose/fx				<0.001
32 Gy in 4 fx	46 (36%)	1 (2%)	45 (54%)	
34 Gy in 5 fx	1 (1%)	0 (0%)	1 (1%)	
36 Gy in 6 fx	82 (64%)	44 (98%)	38 (45%)	
Salvage ADT				0.026
Short term	31 (24%)	14 (31%)	17 (20%)	
Long term	5 (4%)	4 (9%)	1 (1%)	
None	93 (72%)	27 (60%)	66 (79%)	
Post salvage PSA	1.07 (0.44-2.39)	0.60 (0.21-1.77)	1.68 (0.59-2.48)	0.013
Post salvage nadir	0.18 (0.09-1.76)	0.10 (0.05-0.34)	0.23 (0.10-0.72)	0.006
Median follow-up (mo)	77 (49-107)	105 (59-140)	62 (49-86)	<0.001

Table 2. Univariate analysis for predictors of biochemical failure

Variable	p-value
Prior to definitive treatment	
T-stage	0.23
PSA	0.10
Gleason score	0.75
Percent positive cores	0.66
Perineural invasion	0.20
Definitive treatment with ADT	0.31
Following definitive treatment	
PSA nadir	0.86
Disease free interval (months)	0.41
Failure to SHDRBT (months)	0.43
Clinical variables at sHDRBT	
T-stage	0.25
PSA	0.09
Gleason score	0.21
Percent positive cores	0.50
Perineural invasion	0.48

Table 3. Site of failure after salvage HDR brachytherapy

Site	No ⁶⁸ Ga-PSMA PET	⁶⁸ Ga-PSMA PET	Total
Local	5	4	9
Regional	3	0	3
Distant	26	2	28
Locoregional	0	3	3
Local and distant	1	0	1
Regional and distant	1	1	2
Local, regional, and distant	0	1	1
Unknown	22 (38%)	1 (8%)	23
Total	58	12	70

* 2 patients had ⁶⁸Ga-PSMA PET scans prior to sHDRBT and remain biochemically without evidence of disease

Table 4. Toxicity following salvage HDR brachytherapy

	Grade 0	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5
Acute, <3 months						
Genitourinary (n=127)	9 (7%)	62 (48%)	55 (42%)	1 (1%)	0 (0%)	0 (0%)
Gastrointestinal (n=126)	97 (75%)	27 (22%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)
Late, >3 months						
Genitourinary (n=125)	14 (11%)	22 (17%)	82 (63%)	6 (5%)	1 (1%)	0 (0%)
Gastrointestinal (n=126)	95 (73%)	25 (19%)	4 (3%)	1 (1%)	1 (1%)	0 (0%)
Late, >9 months						
Genitourinary (n=118)	19 (14%)	23 (18%)	71 (55%)	5 (4%)	1 (1%)	0 (0%)
Gastrointestinal (n=125)	97 (75%)	23 (18%)	3 (2%)	1 (1%)	1 (1%)	0 (0%)

*If insufficient information documented to grade toxicity, patients were excluded from the analysis

Figure1a

Months	6	24	36	48	90
Number events (death)	1	3	6	7	12
Number at risk	128	124	111	93	42
Censored, lack of follow-up	0	2	12	29	75

Figure1b

Months	6	15	24	36	48	70	90
Number events (failure)	2	6	9	16	22	39	45
Number at risk	127	123	117	103	86	53	39
Censored, lack of follow-up	0	0	3	10	23	37	45

Figure1c

Months	6	12	24	36	48	70	90
Number events (stricture)	2	5	7	9	11	15	19
Number dead w/o stricture	1	1	3	4	6	7	8
Number at risk	126	123	118	104	86	53	31
Censored, lack of follow-up	0	0	2	12	26	54	71

Click here to access/download
Uniform Disclosures Form
Mack_Roach.pdf

[Click here to access/download](#)
Uniform Disclosures Form
ICHsu.pdf